Feraccru® Real World Effectiveness Study in Hospital Practice ( FRESH )

NCT03247816 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 59

Last updated 2020-10-23

Study results available
· View outcomes & findings →

Summary

The aim of the study is to understand the early experiences of Feraccru® in patients with inflammatory bowel disease (IBD) and iron deficiency anaemia (IDA) in the UK, including treatment effectiveness, patterns of use and tolerability.

Conditions

  • Anemia, Iron Deficiency
  • Inflammatory Bowel Diseases

Sponsors & Collaborators

  • Shield Therapeutics

    lead INDUSTRY

Eligibility

Min Age
18 Years
Max Age
99 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2017-08-14
Primary Completion
2018-03-01
Completion
2018-10-01

Countries

  • United Kingdom

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03247816 on ClinicalTrials.gov